Seldi-tof-ms Protein Chip Technology Screening Study Of Hormone Refractory Prostate Cancer-specific Serum Protein

Objictive:To study biomarkers by use of SELDI-TOF mass spectrometry in the serum from androgen-dependent prostate cancer and hormone-refractory prostate cancer.Methods:The serum from 21 patients starting hormonal therapy on a clinical trial enrolling patients with bone metastases was identified and comprised the androgen sensitive cohort. The serum from 21 patients with androgen insensitive disease was obtained from patients prior to starting therapy on a hormone refractory prostate cancer clinical trial. The latter were confirmed to have castrate levels of testosterone and be progressing on androgen ablation. SELDI mass spectroscopy using IMAC-Cu chips (Ciphergen: Fremont, CA) was employed. The data of spectra were analyzed by bioinformatics tools Biomarker Wizard.Results:Compared with the spectra of androgen-dependent prostate cancer patients, there were 6 potential markers detected in the spectra of the hormone-refractory prostate cancer patients (P<0.05) .Two masses with an average mass of 2949 Da,4638 Da were up-regulared in hormone-refractory prostate cancer patients compared with androgen-dependent prostate cancer patients, and four masses of 4205 Da,5185 Da, 5058 Da, 7750 Da were down- regulared. Respectively applies 5185 Da and 4205 Da through to receive under trying operating characteristics curve protein diagnosis hormone-refractory prostate cancer its curve the area respectively were 0.865, 0.838; the sensitivity respectively were 0.867, 0.800; the peculiarity respectively were 0.769, 0.885. Though searching Swiss-prot database,there were two protein might be potential biomarker,they were Apelin-36 and Protein p8 MTCP-1,respectively.Conclusion:Serum proteomic profiling can distinguish androgen sensitive from androgen resistant disease more accurately,these proteins were possibly playing the influential role in the hormone-refractory prostate cancers morbidity process. This technology may be able to identify proteins that drive the androgen resistant state and provide signatures for patients who may respond to second line hormonal therapy.